Registry study of autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy

Evidence-generating research to clarify the current status and establish treatments for autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) - Evidence-generating research to clarify the current status and establish treatments for GFAP-A

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054387

Enrollment

500

Registered

2024-07-01

Start date

2025-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Autoimmune GFAP astrocytopathy (GFAP-A) patients with anti-GFAP antibodies in cerebrospinal fluide detected by cell-based and tissue-based assays 2) GFAP-A patients with written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: GFAP-A patients who are judged to be inappropriate as included subjects by researcher, etc.

Design outcomes

Primary

Measure	Time frame
1) presence or absence of death 2) Clinical Assessment Scale in Autoimmune Encephalitis (CASE) 3) outcomes of modified Rankin Scale (mRS)	—

Countries

Japan

Contacts

Public ContactAkio Kimura

Gifu University Graduate School of Medecine Department of Neurology

kimura.akio.k8@f.gifu-u.ac.jp0582306253

Outcome results